Amgen Competitors

AMGN Stock  USD 316.04  1.00  0.32%   
Amgen Inc competes with Merck, AbbVie, Gilead Sciences, Johnson Johnson, and Bristol Myers; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Amgen competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Amgen to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Amgen Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Amgen competition on your existing holdings.
  
At this time, Amgen's Return On Tangible Assets are very stable compared to the past year. As of the 21st of March 2025, Return On Capital Employed is likely to grow to 0.21, while Return On Assets are likely to drop 0.04. At this time, Amgen's Fixed Asset Turnover is very stable compared to the past year. As of the 21st of March 2025, Asset Turnover is likely to grow to 0.51, while Other Current Assets are likely to drop about 2.8 B.
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
313.54315.04316.54
Details
Intrinsic
Valuation
LowRealHigh
300.94302.44346.54
Details
Naive
Forecast
LowNextHigh
308.06309.55311.05
Details
32 Analysts
Consensus
LowTargetHigh
290.61319.35354.48
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Amgen. Your research has to be compared to or analyzed against Amgen's peers to derive any actionable benefits. When done correctly, Amgen's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Amgen Inc.

Amgen Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Amgen and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Amgen and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Amgen Inc does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
JNJGILD
GILDABBV
JNJABBV
LLYJNJ
LLYABBV
LLYGILD
  
High negative correlations   
LLYMRK
JNJMRK
BIIBJNJ
ABBVMRK
GILDMRK
BIIBGILD

Risk-Adjusted Indicators

There is a big difference between Amgen Stock performing well and Amgen Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Amgen's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

Cross Equities Net Income Analysis

Compare Amgen Inc and related stocks such as Merck Company, AbbVie Inc, and Gilead Sciences Net Income Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
2010201120122013201420152016201720182019202020212022202320242025
MRK539.9 M6.3 B6.7 B4.4 B11.9 B4.4 B5.7 B2.6 B6.2 B9.8 B7.1 B13 B14.5 B365 M17.1 B18 B
ABBV4.6 B3.4 B5.3 B4.1 B1.8 B5.1 BB5.3 B5.7 B7.9 B4.6 B11.5 B11.8 B4.9 B4.3 B6.2 B
GILD(4 M)2.8 B2.6 B3.1 B12.1 B18.1 B13.5 B4.6 B5.5 B5.4 B89 M6.2 B4.6 B5.7 B480 M456 M
JNJ613.7 M9.7 B10.9 B13.8 B16.3 B15.4 B16.5 B1.3 B15.3 B15.1 B14.7 B20.9 B17.9 B35.2 B14.1 B9.6 B
BMY1.1 B3.7 BB2.6 BB1.6 B4.5 BBB3.4 B(9 B)B6.3 BB(8.9 B)(8.5 B)
PFE579.7 M10 B14.6 B22 B9.1 BB7.2 B21.3 B11.2 B16.3 BB22 B31.4 B2.1 BB8.4 B
LLY517.6 M4.3 B4.1 B4.7 B2.4 B2.4 B2.7 B(204.1 M)3.2 B4.6 B6.2 B5.6 B6.2 B5.2 B10.6 B11.1 B
BIIB(19.1 M)1.2 B1.4 B1.9 B2.9 B3.5 B3.7 B2.5 B4.4 B5.9 BB1.6 BB1.2 B1.6 B1.2 B
JavaScript chart by amCharts 3.21.15Macroaxis Charts20122014201620182020202220241020406080100120140
JavaScript chart by amCharts 3.21.15Merck Companytotal: 60.94AbbVie Inctotal: 68.93Gilead Sciencestotal: 214.32Johnson Johnsontotal: 72.13Bristol Myers Squibbtotal: 62.23Pfizer Inctotal: 56.43Eli Lilly andtotal: 109.41Biogen Inctotal: 165.02

Amgen Inc and related stocks such as Merck Company, AbbVie Inc, and Gilead Sciences Net Income description

Net income is one of the most important fundamental items in finance. It plays a large role in Amgen Inc financial statement analysis. It represents the amount of money remaining after all of Amgen Inc operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Amgen Competitive Analysis

The better you understand Amgen competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Amgen's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Amgen's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
AMGN MRK ABBV GILD JNJ BMY PFE LLY BIIB
 0.32 
 316.04 
Amgen
 1.71 
 93.11 
Merck
 0.92 
 210.01 
AbbVie
 1.14 
 107.08 
Gilead
 0.37 
 163.63 
Johnson
 1.08 
 61.07 
Bristol
 0.34 
 26.28 
Pfizer
 0.59 
 837.57 
Eli
 0.34 
 140.90 
Biogen
Market Volatility
(90 Days Market Risk)
Market Performance
(90 Days Performance)
Odds of Financial Distress
(Probability Of Bankruptcy)
Current Valuation
(Equity Enterprise Value)
Buy or Sell Advice
(Average Analysts Consensus)
Trade Advice
(90 Days Macroaxis Advice)
Current Ratio
Net Asset
Profit Margin
EBITDA
Operating Margin
Current Valuation
Price To Book
Retained Earnings
Current Asset
Five Year Return
Beta
Number Of Employees
Shares Outstanding
Cash Flow From Operations
Annual Yield
Total Debt
Return On Equity
Return On Asset
Number Of Shares Shorted
Book Value Per Share
Current Liabilities
Total Asset
Short Ratio
Target Price
Last Dividend Paid
Debt To Equity
Shares Owned By Institutions
Market Capitalization
Price To Earning
Price To Earnings To Growth
Price To Sales
Net Income
Earnings Per Share
Shares Owned By Insiders
Revenue
Working Capital
Cash And Equivalents
Cash Per Share
Gross Profit
Day Typical Price
Accumulation Distribution
Daily Balance Of Power
Period Momentum Indicator
Rate Of Daily Change
Day Median Price
Price Action Indicator
Relative Strength Index
Coefficient Of Variation
Mean Deviation
Jensen Alpha
Total Risk Alpha
Sortino Ratio
Downside Variance
Standard Deviation
Kurtosis
Potential Upside
Treynor Ratio
Maximum Drawdown
Variance
Market Risk Adjusted Performance
Risk Adjusted Performance
Skewness
Semi Deviation
Information Ratio
Value At Risk
Expected Short fall
Downside Deviation
Semi Variance

Amgen Competition Performance Charts

JavaScript chart by amCharts 3.21.152025FebMarFeb 11Feb 16Feb 21Feb 26MarMar 08Mar 13Mar 18-10%0%10%20% Show all
JavaScript chart by amCharts 3.21.15Amgen Inc Merck Company AbbVie Inc Gilead Sciences Johnson Johnson Bristol Myers Squibb Pfizer Inc Eli Lilly Biogen Inc Dow Jones Industrial

Five steps to successful analysis of Amgen Competition

Amgen's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Amgen Inc in relation to its competition. Amgen's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Amgen in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Amgen's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Amgen Inc, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Amgen position

In addition to having Amgen in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Gold and Gold Mining Thematic Idea Now

Gold and Gold Mining
Gold and Gold Mining Theme
Large and mid-size companies, ETFs and funds that are either investing, exploring or producing, gold or indirectly involved in trading or making gold products. The Gold and Gold Mining theme has 73 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Gold and Gold Mining Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Amgen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Amgen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Amgen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Amgen Inc Stock:
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amgen. If investors know Amgen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amgen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.19)
Dividend Share
9
Earnings Share
7.56
Revenue Per Share
62.242
Quarterly Revenue Growth
0.109
The market value of Amgen Inc is measured differently than its book value, which is the value of Amgen that is recorded on the company's balance sheet. Investors also form their own opinion of Amgen's value that differs from its market value or its book value, called intrinsic value, which is Amgen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amgen's market value can be influenced by many factors that don't directly affect Amgen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amgen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Amgen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amgen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.